KROS

Keros TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$23.58

+124.6% vs current

Most likely

Base case

60%

Probability

Target price

$19.22

+83.0% vs current

B-

Bear case

20%

Probability

Target price

$13.10

+24.8% vs current

AI sentiment snapshot

Latest data as of 2025-11-13

AI commentary

Market tone is cautiously constructive around clinical milestones but sensitive to binary readouts; recent anchor price reflects rapprochement after earlier volatility [#ANCHOR]. Short-term sentiment is driven by funding and readout timelines, while longer-term views hinge on data and partnering prospects [#ANCHOR].

RankAlpha Sentiment AI - 2025-11-13

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

-eventClinical readout for lead hematology program (mid-stage)High impact

Mid-stage efficacy/safety readout could re-rate the stock materially if positive; downside risk on negative results [#ANCHOR].

-catalystQuarterly operating update / cash runway disclosureHigh impact

Balance-sheet updates or guidance could produce near-term volatility and downside if runway is shorter than expected [#ANCHOR].

-catalystPartnership or licensing deal for commercial/late-stage developmentHigh impact

A strategic BD/partnering deal would de-risk development capital needs and likely drive multi-quarter upside [#ANCHOR].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2025-11-13 • Updated nightlySource: Internal modelMethodology